Upcoming Research

A retrospective study using thrombelastography has suggested a therapeutic range using antiplatelet drugs that is effective in containing both bleeding and ischemic events.¹

To demonstrate its ability to provide guidance in optimized, personalized therapy in high-risk cardiovascular patients, CORA™ technology will be used in a large-scale, multi-center clinical study. The new study will incorporate newer antiplatelet drugs in addition to standard clopidogrel (Plavix®), titrating to therapeutic values.

Coramed received FDA marketing clearance of the new instrument and assays in 2015 and is seeking research partners at this time.

Contact us to discuss potential opportunities.

 

 

 

¹Gurbel PA et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J. Aug 2010;160(2):346-354.

Plavix is a registered trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.

 

Clinical Evaluations

New CORA technology has great potential across the complete continuum of care.